Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline

STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more

Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis

Myricx Bio, a cancer therapy spinout from the Francis Crick Institute and Imperial College London, has agreed to be acquired by Novartis in

Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal

Novartis to buy UK biotech in $1.5bn deal

RQ Bio secures $115M Series A for virus-targeting antibody pipeline

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.